Everolimus-eluting bioresorbable scaffolds for coronary artery disease

New England Journal of Medicine

Volumn 373, Issue 20, 2015, Pages 1905-1915

  Ellis, Stephen G ^a   Kereiakes, Dean J ^b   Metzger, D Christopher ^d   Caputo, Ronald P ^e   Rizik, David G ^f   Teirstein, Paul S ^g   Litt, Marc R ⁱ   Kini, Annapoorna ^c   Kabour, Ameer ^j   Marx, Steven O ^k   Popma, Jeffrey J ^m   McGreevy, Robert ^h   Zhang, Zhen ^h   Simonton, Charles ^h   Stone, Gregg W ^k,l  

^a LERNER RESEARCH INSTITUTE   (United States)

^b The Carl & Edyth Lindner Center for Research & Education   (United States)

^c ST VINCENT MERCY MEDICAL CENTER   (United States)

^d Wellmont Holston Valley Medical Center   (United States)

^e ST JOSEPH S HOSPITAL HEALTH CENTER   (United States)

^f Virginia G Piper Cancer Center   (United States)

^g SCRIPPS CLINIC   (United States)

^h ABBOTT VASCULAR   (United States)

ⁱ BAPTIST MEDICAL CENTER   (United States)

^j MOUNT SINAI MEDICAL CENTER   (United States)

^k NewYork Presbyterian Hospital   (United States)

^l CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^m BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHROMIUM; COBALT; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; METAL;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DEVICE SAFETY; DRUG ELUTING CORONARY STENT; EVEROLIMUS ELUTING COBALT CHROMIUM STENT; EVEROLIMUS ELUTING CORONARY STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STENT THROMBOSIS; TREATMENT OUTCOME; ADVERSE EFFECTS; AGED; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; BIODEGRADABLE IMPLANT; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ELUTING STENT; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROSTHESIS; RESTENOSIS;

ABSORBABLE IMPLANTS; AGED; ANGINA PECTORIS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; MALE; METALS; MIDDLE AGED; PROSTHESIS DESIGN;

EID: 84946835771     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1509038     Document Type: Article

References (32)

1. Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive metaanalysis of randomized trials and observational studies. Circulation 2009; 119: 3198-206.
2. Bangalore S, Kumar S, Fusaro M, et al. Short-and long-term outcomes with drugeluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 2012; 125: 2873-91.
3. Gada H, Kirtane AJ, Newman W, et al. Five-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial. JACC Cardiovasc Interv 2013; 6: 1263-6.
4. Palmerini T, Benedetto U, Biondi-Zoccai G, et al. Long-term safety of drugeluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 2015; 65: 2496-507.
5. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
6. Otsuka F, Vorpahl M, Nakano M, et al. Pathology of second-generation everolimuseluting stents versus first-generation sirolimus-and paclitaxel-eluting stents in humans. Circulation 2014; 129: 211-23.
7. De Bruyne B, Pijls NHJ, Kalesan B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 2012; 367: 991-1001.
8. Cohen DJ, Van Hout B, Serruys PW, et al. Quality of life after PCI with drugeluting stents or coronary-artery bypass surgery. N Engl J Med 2011; 364: 1016-26.
9. Sen H, Lam MK, L.wik MM, et al. Clinical events and patient-reported chest pain in all-comers treated with Resolute Integrity and Promus Element stents. JACC Cardiovasc Interv 2015; 8: 889-99.
10. Versaci F, Gaspardone A, Tomai F, et al. Chest pain after coronary artery stent implantation. Am J Cardiol 2002; 89: 500-4.
11. Ong P, Athanasiadis A, Perne A, et al. Coronary vasomotor abnormalities in patients with stable angina after successful stent implantation but without in-stent restenosis. Clin Res Cardiol 2014; 103: 11-9.
12. Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J 2012; 33: 16-25b.
13. Serruys PW, Onuma Y, Garcia-Garcia HM, et al. Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention 2014; 9: 1271-84.
14. Simsek C, Karanasos A, Magro M, et al. Long-term invasive follow-up of the everolimus-eluting bioresorbable vascular scaffold: five-year results of multiple invasive imaging modalities. EuroIntervention 2014 October 28 (Epub ahead of print).
15. Capodanno D, Gori T, Nef H, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. Euro-Intervention 2015; 10: 1144-53.
16. Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimuseluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 2015; 385: 43-54.
17. Puricel S, Arroyo D, Corpataux N, et al. Comparison of everolimus-and biolimuseluting coronary stents with everolimuseluting bioresorbable vascular scaffolds. J Am Coll Cardiol 2015; 65: 791-801.
18. Kimura T, Kozuma K, Tanabe K, et al. A randomized trial evaluating everolimuseluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J 2015; pii: ehv435.
19. Kereiakes DJ, Ellis SG, Popma JJ, et al. Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: design of and rationale for the ABSORB III randomized trial. Am Heart J 2015; 170: 641-51.
20. Food and Drug Administration. Guidance for industry: non-inferiority clinical trials. March 2010 (http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm202140.pdf).
21. Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med 1990; 9: 1447-54.
22. Vlachojannis GJ, Smits PC, Hofma SH, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with coronary artery disease: three-year follow-up of the COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) trial. Euro-Intervention 2015; 11: 272-9.
23. Yamaji K, Kimura T, Morimoto T, et al. Very long-term (15 to 20 years) clinical and angiographic outcome after coronary bare metal stent implantation. Circ Cardiovasc Interv 2010; 3: 468-75.
24. Lane JP, Perkins LEL, Sheehy AJ, et al. Lumen gain and restoration of pulsatility after implantation of a bioresorbable vascular scaffold in porcine coronary arteries. JACC Cardiovasc Interv 2014; 7: 688-95.
25. Otsuka F, Pacheco E, Perkins LEL, et al. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model. Circ Cardiovasc Interv 2014; 7: 330-42.
26. Abizaid A, Ribamar Costa J Jr, Bartorelli AL, et al. The ABSORB EXTEND study: preliminary report of the twelvemonth clinical outcomes in the first 512 patients enrolled. EuroIntervention 2015; 10: 1396-401.
27. Stone GW, Kirtane A. Bare metal and drug-eluting coronary stents. In: Topol EJ, Teirstein PS, eds. Textbook of interventional cardiology. 6th ed. Philadelphia: Elsevier Saunders, 2012: 171-96.
28. Kuramitsu S, Iwabuchi M, Haraguchi T, et al. Incidence and clinical impact of stent fracture after everolimus-eluting stent implantation. Circ Cardiovasc Interv 2012; 5: 663-71.
29. Mansour M, Carrozza JP Jr, Kuntz RE, et al. Frequency and outcome of chest pain after two new coronary interventions (atherectomy and stenting). Am J Cardiol 1992; 69: 1379-82.
30. B.sner S, Becker A, Haasenritter J, et al. Chest pain in primary care: epidemiology and pre-work-up probabilities. Eur J Gen Pract 2009; 15: 141-6.
31. Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010; 362: 1663-74.
32. Stone GW, Midei M, Newman W, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008; 299: 1903-13.